LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin ...

LONDON, March 6, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose dis ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary ...

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Nucala® (mepolizumab), the first and only biologic add-on therapy for people 12 years and older with severe asthma with an eosinophilic ...

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint of reduction in ...

(RTTNews) - GlaxoSmithKline plc (GSK, GSK.L) said that the US Food and Drug Administration has approved Nucala or mepolizumab, a monoclonal antibody that targets interleukin-5 (IL-5), as a ...

LONDON--(BUSINESS WIRE)--GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe exacerbations in a year, according to results published in The New England ...

LONDON, Dec. 12, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted ...

First IL-5 therapy approved as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps to target eosinophilic inflammation Fourth indication for mepolizumab in the ...

GSK ANNOUNCES NUCALA® (mepolizumab), NOW AVAILABLE IN THE US FOR SUB-GROUP OF PATIENTS WITH SEVERE ASTHMA. Dec 2, 2015 11:11am. Biotech. RESEARCH TRIANGLE PARK, N.C., Dec. 2, 2015 /PRNewswire/-- ...